Octapharma produces human proteins from human plasma and human cell lines, developing coagulation factor concentrates for bleeding disorders, immunoglobulin products for immune-mediated diseases, and proteins for critically ill patients. The company operates plasma donation centers in the US and Germany plus production facilities across Austria, Germany, France, Mexico, and Sweden, handling plasma fractionation, purification, R&D, packaging, and distribution. The company maintains a robust supply chain with over 190 plasma donation centers and advanced R&D sites supporting its therapeutic portfolio.
Cyborg Score Rationale
With 11,908 employees serving patients in 118 countries and €3.47 billion in revenue (2024), Octapharma demonstrates scale and market reach in a specialized sector. The company's vertically integrated supply chain, established product portfolio, and family-ownership provide stability, though private status limits transparency and the plasma-derived therapeutics market faces supply constraints and regulatory complexities.
Top Insights
Octapharma generated €3.47 billion in revenue in 2024, demonstrating strong market demand for human protein-based therapeutics and global pricing power in a specialized biopharmaceutical segment.
Octagam® 10% (intravenous immunoglobulin) has gained market preference by eliminating sucrose, reducing risks of thrombosis and renal dysfunction compared to competing IGIV products, driving higher adoption among healthcare providers.
In February 2026, Octapharma invested in Abram Scientific's Series A funding round, signaling strategic expansion into complementary therapeutic innovation while maintaining financial discipline as a private, unfunded entity.
Named Competitors
Immunoglobulin and coagulation therapies — Leading global plasma-derived biopharmaceutical manufacturer
Plasma-derived therapeutics — Major producer of plasma-derived medicines and blood screening solutions
Immunoglobulin and albumin products — Global healthcare manufacturer with plasma-based therapeutic portfolio
Recent Developments
(February 2026) Octapharma secures stake in Abram Scientific Series A funding
(December 2024) Supply chain efficiency partnership with Kinaxis
(May 2025) Phase 3 pediatric neuropsychiatric disorder study results published
Open the full interactive Octapharma AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.